Literature DB >> 30190854

Immune checkpoint inhibitors in melanoma.

Adam J Cooper1,2,3,1,2,3, Matteo S Carlino1,2,3,4,1,2,3,4, Richard F Kefford1,2,3,4,5,1,2,3,4,5.   

Abstract

The potential to harness the power of the immune system and effectively treat patients with metastatic melanoma is finally being realized with the advent of immune checkpoint inhibitors. These new therapies herald a new era in the treatment of melanoma with the potential to produce very durable responses and possible cure for a subset of patients, though bring with them challenges including novel toxicities and nonconventional response patterns. This article reviews the currently available immune checkpoint inhibitors, potential biomarkers to predict response and promising investigational approaches including combination therapies.

Entities:  

Keywords:  anti-CTLA4; anti-PD-1; anti-PD-L1; checkpoint inhibitor; immunotherapy; ipilimumab; melanoma; nivolumab; pembrolizumab

Year:  2015        PMID： 30190854      PMCID： PMC6094677          DOI： 10.2217/mmt.15.17

Source DB:  PubMed          Journal:  Melanoma Manag        ISSN： 2045-0885


  70 in total

1.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4.

Authors:  Kimberly E Beck; Joseph A Blansfield; Khoi Q Tran; Andrew L Feldman; Marybeth S Hughes; Richard E Royal; Udai S Kammula; Suzanne L Topalian; Richard M Sherry; David Kleiner; Martha Quezado; Israel Lowy; Michael Yellin; Steven A Rosenberg; James C Yang
Journal:  J Clin Oncol       Date:  2006-05-20       Impact factor: 44.544

2.  Arthritis and tenosynovitis associated with the anti-PD1 antibody pembrolizumab in metastatic melanoma.

Authors:  Matthew M K Chan; Richard F Kefford; Matteo Carlino; Arthur Clements; Nicholas Manolios
Journal:  J Immunother       Date:  2015-01       Impact factor: 4.456

3.  Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study.

Authors:  Jedd D Wolchok; Bart Neyns; Gerald Linette; Sylvie Negrier; Jose Lutzky; Luc Thomas; William Waterfield; Dirk Schadendorf; Michael Smylie; Troy Guthrie; Jean-Jacques Grob; Jason Chesney; Kevin Chin; Kun Chen; Axel Hoos; Steven J O'Day; Celeste Lebbé
Journal:  Lancet Oncol       Date:  2009-12-08       Impact factor: 41.316

Review 4.  Spontaneous regression of metastases from melanoma: review of the literature.

Authors:  Louise Vennegaard Kalialis; Krzysztof T Drzewiecki; Helle Klyver
Journal:  Melanoma Res       Date:  2009-10       Impact factor: 3.599

5.  Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Authors:  Luis H Camacho; Scott Antonia; Jeffrey Sosman; John M Kirkwood; Thomas F Gajewski; Bruce Redman; Dmitri Pavlov; Cecile Bulanhagui; Viviana A Bozon; Jesus Gomez-Navarro; Antoni Ribas
Journal:  J Clin Oncol       Date:  2009-01-12       Impact factor: 44.544

6.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

7.  BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

Authors:  Laurent Derré; Jean-Paul Rivals; Camilla Jandus; Sonia Pastor; Donata Rimoldi; Pedro Romero; Olivier Michielin; Daniel Olive; Daniel E Speiser
Journal:  J Clin Invest       Date:  2009-12-28       Impact factor: 14.808

8.  Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.

Authors:  Paolo A Ascierto; Ester Simeone; Diana Giannarelli; Antonio M Grimaldi; Anna Romano; Nicola Mozzillo
Journal:  J Transl Med       Date:  2012-05-28       Impact factor: 5.531

9.  Ipilimumab for advanced melanoma: experience from the Spanish Expanded Access Program.

Authors:  Alfonso Berrocal; Ana Arance; Jose Antonio Lopez Martin; Virtudes Soriano; Eva Muñoz; Lorenzo Alonso; Enrique Espinosa; Pilar Lopez Criado; Javier Valdivia; Salvador Martin Algarra
Journal:  Melanoma Res       Date:  2014-12       Impact factor: 3.599

10.  Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Jun Zhou; Zhiwan Dong; Sapna Tandon; Deborah Kuk; Katherine S Panageas; Philip Wong; Xinqi Wu; Jarushka Naidoo; David B Page; Jedd D Wolchok; F Stephen Hodi
Journal:  Cancer Immunol Res       Date:  2014-02       Impact factor: 11.151
View more
  1 in total

1.  Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.

Authors:  Náthali Felícia Mineiro Dos Santos Garrett; Ana Cristina Carvalho da Costa; Elaine Barros Ferreira; Giovanni Damiani; Paula Elaine Diniz Dos Reis; Christiane Inocêncio Vasques
Journal:  PLoS One       Date:  2021-08-06       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.